RESEARCH TRIANGLE PARK, N.C., Nov. 2 /PRNewswire-FirstCall/ -- Biotechnology company Icoria, Inc. today announced that on November 14 it will report its 2005 third quarter financial results for the period ending September 30, 2005.
The company's management team will conduct a conference call and webcast to discuss the results on Tuesday, November 15, at 8:30 a.m. ET. Interested participants should call 1-800-231-9012 or, for those calling internationally, 1-719-457-2617. The conference call ID number is 2030345. Icoria encourages participants to dial in 10 minutes before the call commences.
The webcast can be accessed from Icoria's web site at http://www.icoria.com by clicking on the Investor Relations link. For those unable to participate, replays of the call may be heard online at http://www.icoria.com. Supplemental information will also be available online.
On September 20, 2005, Icoria announced that it had executed a merger agreement with Clinical Data Inc. whereby Clinical Data will acquire Icoria in an all-stock transaction valued at up to $12.5 million. The acquisition is expected to close late this year or in early 2006, pending approval by Icoria's shareholders. More information on this transaction is available at www.icoria.com. More information on Clinical Data is available at www.clda.com.
Icoria, Inc. is a biotechnology company focused on the discovery of novel, multi-parameter biomarkers using its unique multi-platform approach. Icoria intends to use these future biomarkers internally to develop multi-analyte diagnostics to define and grade pathology or disease state with a high level of specificity and sensitivity, and use its technology to help collaborators and customers develop better, safer drugs and diagnostics and to identify targets, leads and drug/diagnostic combinations for liver injury, metabolic disorders and cancer. Icoria's shares trade on the over the counter bulletin board.
This press release contains forward-looking statements including, but not limited to, Icoria's acquisition by Clinical Data, Inc., the Company's expectations for its healthcare based business model and its biomarker discovery platform. Such forward-looking statements are based on management's current expectations and are subject to a number of risks, factors and uncertainties that may cause actual results, events and performance to differ materially from those referred to in the forward-looking statements. These risks, factors and uncertainties include, but are not limited to, Icoria's ability to identify biomarkers, early stage of development, history of net losses, technological and product development uncertainties, reliance on research collaborations, uncertainty of additional funding and ability to protect its patents and proprietary rights. Certain of these and other risks are identified in Icoria's Quarterly Reports on Form 10-Q for the period ended June 30, 2005, as amended, and its Annual Report on Form 10-K for the year ended December 31, 2004, both as filed with the Securities and Exchange Commission. The Company does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in our expectations, except as may be required by law.